Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082394 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00082394: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00082394 is a Phase 4 study that has completed, run by GlaxoSmithKline. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082394, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerability and efficacy of the investigational drugs were measured and compared.
Interventions
- DRUG atazanavir
- DRUG Combivir
- DRUG Trizivir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-04-26 |
| Est. Completion | 2006-03-01 |
| Phase | Phase 4 |
What the finished NCT00082394 record still lists
NCT00082394 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which atazanavir is the first listed.
NCT00082394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00082394 about?
NCT00082394 is a clinical study titled "A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV". The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerabil...
What is the current status of trial NCT00082394?
This trial is currently completed. It is a Phase 4 study. The study started on 2004-04-26. Estimated completion is 2006-03-01.
What interventions are being tested in trial NCT00082394?
The interventions under investigation include: atazanavir (DRUG), Combivir (DRUG), Trizivir (DRUG).
Who is sponsoring clinical trial NCT00082394?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI